Dossier assessment
Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with moderate to severe plaque psoriasis
Proof of considerable added benefit for patients with inadequate response or intolerance to systemic therapy. Due to a lack of relevant study data, an added benefit is not proven for patients who are not candidates for conventional therapy in the framework of a first systemic therapy.
Additional information
Federal Joint Committee (G-BA)
2019-11-22 A G-BA decision was published.
Project details
- Project no.
- A19-41
- Commission
- Commission awarded on 03.05.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Addendum
Risankizumab (plaque psoriasis) - Addendum to Commission A19-41
Status: Commission completed
-
Addendum
Risankizumab (plaque psoriasis) - Second Addendum to Commission A19-41
Status: Commission completed
-
Dossier assessment
Risankizumab (plaque psoriasis in children and adolescents) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Risankizumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Risankizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed